BackIdeaya Biosciences Overview
Ideaya Biosciences Inc

Ideaya Biosciences Target Price

Analysts' 12-month price predictions for IDYA.

Get informed when a big investor buys or sells

+ Follow

Share Price

$36.65

Average Target Price

$57.4056.6% upside

5 analysts in the last 4 months

High: $65 | Low: $48

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-07-07Truist FinancialGregory Renza$6371.9% upsideOpen
2026-07-07RBC Capital$4831% upsideOpen
2026-04-14Wedbush$5858.3% upsideOpen
2026-04-14RBC Capital$5344.6% upsideOpen
2026-04-13Truist Financial$6577.4% upsideOpen
2026-02-18Wedbush$5241.9% upsideOpen
2026-01-21RBC Capital$4522.8% upsideOpen
2026-01-06Truist FinancialGregory Renza$6063.7% upsideOpen
2025-11-24Truist Financial$5961% upsideOpen
2025-10-21New Street$3018.1% downsideOpen
2025-10-21RBC Capital$4111.9% upsideOpen
2025-09-17Guggenheim$5036.4% upsideOpen
2025-09-09RBC CapitalGregory Renza$383.7% upsideOpen
2025-09-08OppenheimerMatthew Biegler$361.8% downsideOpen
2025-09-04JMP Securitieslvan Tuerkcan$4111.9% upsideOpen
2025-09-04Barclays$409.1% upsideOpen
2024-11-05Leerink PartnersAndrew Berens$2726.3% downsideOpen
2024-10-24UBSDavid Dai$5036.4% upsideOpen
2024-09-25Mizuho SecuritiesGraig Suvannavejh$5550.1% upsideOpen
2024-09-23Goldman SachsCorinne Jenkins$4831% upsideOpen
2024-09-23Stifel NicolausBen Burnett$6680.1% upsideOpen
2024-09-23BTIGJustin Zelin$6269.2% upsideOpen
2024-09-10Stifel NicolausBen Burnett$6885.5% upsideOpen
2024-08-27CitigroupYigal Nochomovitz$5858.3% upsideOpen
2024-08-07OppenheimerMatthew Biegler$5344.6% upsideOpen
2024-07-10RBC CapitalGregory Renza$6166.4% upsideOpen
2024-07-08Mizuho SecuritiesGraig Suvannavejh$5036.4% upsideOpen
2024-06-03Stifel NicolausBen Burnett$6371.9% upsideOpen
2022-12-28Capital One Financial$2920.9% downsideOpen
2022-09-13Guggenheim$3212.7% downsideOpen
2022-08-18Oppenheimer$2045.4% downsideOpen
2022-08-16Robert W. Baird$1850.9% downsideOpen